Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?
B Sigvant, M Henriksson, F Lundin… - European Journal of …, 2011 - academic.oup.com
… of this analysis was to evaluate the cost-effectiveness of … subjects should be offered anti-platelet
therapy for CV risk … when calculating incremental cost-effectiveness ratios (defined as …
therapy for CV risk … when calculating incremental cost-effectiveness ratios (defined as …
[HTML][HTML] Clinical and economic outcomes among nonvalvular atrial fibrillation patients with coronary artery disease and/or peripheral artery disease
… Patient data were assessed from the day after the index date … treatment effect using a
logistic model with two treatment … potential confounding factors for treatment choice (warfarin, …
logistic model with two treatment … potential confounding factors for treatment choice (warfarin, …
… and economic impact of rivaroxaban plus aspirin vs. aspirin alone as a secondary prophylaxis in patients with chronic and symptomatic peripheral arterial disease in …
… reduction therapy, antiplatelet therapy, anticoagulants, peripheral … Prior cost-effectiveness
analyses of rivaroxaban conducted … offer an effective treatment strategy option for patients with …
analyses of rivaroxaban conducted … offer an effective treatment strategy option for patients with …
The burden of peripheral artery disease and the role of antiplatelet therapy
… symptoms that include assessment of exertional limitation, … , clopidogrel is the thienopyridine
of choice in patients who are … Impact of renal insufficiency on mortality in advanced lower …
of choice in patients who are … Impact of renal insufficiency on mortality in advanced lower …
Health economic analysis of antiplatelet therapy for acute coronary syndromes in the context of five eastern Asian countries
B Wu, RG Tobe, Y Liu, B He - Clinical Drug Investigation, 2018 - Springer
… to evaluate the cost-effectiveness of dual antiplatelet therapy in … Incremental cost-effectiveness
ratios (ICERs) presented as … healthcare, which might affect the cost-effectiveness results. …
ratios (ICERs) presented as … healthcare, which might affect the cost-effectiveness results. …
A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone
MD Schleinitz, PA Heidenreich - Annals of internal medicine, 2005 - acpjournals.org
… To assess the cost-effectiveness of clopidogrel plus aspirin … artery disease and to explore
the optimal duration of therapy, … of cost-effectiveness" has serious economic implications if …
the optimal duration of therapy, … of cost-effectiveness" has serious economic implications if …
Diagnosis and management of lower limb peripheral arterial disease: summary of NICE guidance
J Layden, J Michaels, S Bermingham, B Higgins - Bmj, 2012 - bmj.com
… of high blood pressure20; and antiplatelet therapy.21 [Based on … evidence; and evaluated
the cost effectiveness of proposed … effect of people’s attitudes and beliefs about their peripheral …
the cost effectiveness of proposed … effect of people’s attitudes and beliefs about their peripheral …
A Budget Impact Analysis to Estimate the Economic Impact of Drug Eluting Balloon for the Treatment of Peripheral Vascular Disease
M Corbo, G Beccagutti, B Manda - Value in Health, 2013 - valueinhealthjournal.com
… of this analysis was to assess the economic impact of DEB … on a patient’s antithrombotic
treatment were estimated by … – 21%) cost-effectiveness ratios (CERs) and indicator of economic …
treatment were estimated by … – 21%) cost-effectiveness ratios (CERs) and indicator of economic …
Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study
…, PLATO Health Economic Substudy Group - European heart …, 2013 - academic.oup.com
… guidelines recommend dual antiplatelet treatment with aspirin [… in the cost-effectiveness
analysis, the cost of study drugs was … artery disease showed similar or higher cost-effectiveness …
analysis, the cost of study drugs was … artery disease showed similar or higher cost-effectiveness …
Prescriber decision-making on antithrombotic therapy after endovascular intervention for peripheral artery disease: a protocol for a discrete choice experiment
A Zhu, R Tang, S Rajendran, H Hajian, SJ Aitken - BMJ open, 2024 - bmjopen.bmj.com
… or Dual-Antiplatelet Therapy trial is the only published randomised control trial assessing
DAPT … by enabling all interaction effects to be investigated, 128 choice sets are not appropriate …
DAPT … by enabling all interaction effects to be investigated, 128 choice sets are not appropriate …